Hepatic Carcinoma
Conditions
Keywords
Hepatic Carcinoma,Three-dimensional Visualization
Brief summary
The aim of the multi-centre study is to evaluate correctly the impact of three dimensional visualization on operation strategy and complications for complex hepatic carcinoma.
Detailed description
Because of the complexity of complex hepatic carcinoma,the limitations of 2D images of CT/MRI and the uncertainty of surgeons'experience, it is difficult for the surgeons to diagnosis and assess the operation strategy accurately based on traditional 2D imaging(CT/MRI).The aim of the multi-centre study is to evaluate correctly the impact of three-dimensional visualization on operation strategy and complications for complex hepatic carcinoma.
Interventions
None listed
Sponsors
Zhujiang Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. 18 years≤ Age ≤70 years 2. Compling with the diagnosis criteria of complex hepatic carcinoma. 3. Primary hepatic carcinoma without intrahepatic or extrahepatic extensive cancer metastasis, the metastatic hepatic carcinoma whose primary focal has been controlled 4. Preoperative liver function is Child - Pugh grade A or B. 5. The patients are volunteered for the study.
Exclusion criteria
1. Patients with mental illness. 2. Patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc.) 3. The patients refused to take part in the study. 4. There are other co-existed malignant tumors. 5. Benign liver diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Impact on operation strategy of three dimensional visualization technique | 2 year | Firstly, the operation strategies based on original CT or MRI image data will be made by the team, Secondly, the operation strategies based on three dimensional reconstruction models will be made by the team, then, actually surgical strategies will be recorded. The change of operation strategy will be assessed by comparing the strategy of the 2D model and 3D model. The change rate of operation strategy will be recorded and presented as percentage. |
| Impact on complication of three dimensional visualization technique | 2 year | The complications are refer to the classification of Clavien-Dindo, including postoperative bleeding, biliary fistula, ascites, postoperative liver failure, renal dysfunction, pleural effusion, abdominal cavity infection, abdominal abscess, incision infection, the occurrence cases of each complication (number) will be recorded. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Stool Routine (the 1th, 3 th,5th, 7th) | 2 year | Defecate occult blood test, Microorganisms (mold, parasites, etc.) |
| Blood biochemistry (the 1th, 3 th,5th, 7th) | 2 year | Serum albumin(g/L), serum pre-albumin(g/L), serum globulin(g/L), total bilirubin(µmol/L), direct bilirubin(µmol/L),serum glutamic-oxaloacetic transaminase (AST, IU/L), serum glutamic pyruvic transaminase (ALT, IU/L), alkaline phosphatase (ALP, IU/L), gamma glutamyl transpeptidase（r-GGT, IU/L） ,Serum creatinine(µmol/L), Urea(mmol/L), Blood sugar(mmol/L) |
| Tumor marker | 2 year | Alpha fetoprotein(AFP, ng/L), Carbohydrate antigen-199(CA-199, ku/L), Carbohydrate antigen-125(CA-125, ku/L), Carcinoembryonic antigen (CEA, ng/L), Carbohydrate antigen-153(CA-153, ku/L) |
| Blood routine examination (the 1th, 3 th, 5th, 7th) | 2 year | Hemoglobin (g/L), Platelet(109/L), and neutrophilic granulocyte percentage (%) |
| Inflammatory biomarkers | 2 year | C-reactive protein, procalcitonin |
| Preoperative viral loading | 2 year | HBV- DNA、HCV- RNA |
| Postoperative results of paraffin wax and immunohistochemical index | 2 year | AFP、Ki67、CK18、CK19、Hepatocyte |
| The blood coagulation function (the 1th, 3th, 5th, 7th) | 2 year | prothrombin time (PT, s), partial thromboplastin time (APTT), international normalized ratio (INR), plasma prothrombin activity (PTA, %), fibrinogen (FIB, g/L), d-dimer(mg/L) |
| Urine routines (the 1th, 3 th,5th, 7th) | 2 year | Urine specific gravity, urine protein(mg/dl), urine sugar(mmol/L), leukocytes in urine(number/ul), urine erythrocyte(number/ul) |
Countries
China
Contacts
Primary ContactFang Chihua, M.D.;Ph.D
Outcome results
None listed